For more than 10 years, Alignment has harnessed trusted artificial intelligence (AI) through AVA – the company's proprietary Medicare Advantage platform – to drive actionable clinical insights that improve senior health outcomes and quality of care. Dr. Bakshandeh's appointment reinforces Alignment's commitment to scaling the platform and further integrating data-driven solutions into every step of the member journey. Using 200+ data sources and 13,000+ attributes to generate secure and personalized insight ...

Group 1 - Alignment Healthcare, Inc. (NASDAQ:ALHC) will release its first quarter 2025 financial results on May 1, 2025, after market close [1] - A conference call to review the financial results will take place at 5 p.m. EDT on the same day [1] - A live audio webcast of the conference call will be available online, with a replay accessible for approximately 12 months [2] Group 2 - Alignment Health focuses on empowering seniors to age well and live vibrant lives through high-quality, low-cost care for Medicare Advantage members [3] - The company partners with trusted local providers to deliver coordinated care, utilizing its customized care model and technology, AVA® [3] - Alignment Health emphasizes its core values of serving the senior community and expanding its national footprint [3]

Alignment Healthcare (ALHC) shares rallied 6.3% in the last trading session to close at $18.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 18.6% gain over the past four weeks.Alignment Healthcare scored a strong price increase, on investors’ optimism driven by reports of Stifel increasing the company’s price target to $23 from $18 with a Buy rating. The development came after Centers for Medicare & Medic ...

Core Insights - Sutter Health and Alignment Healthcare have renewed their agreement, ensuring continued in-network access for Alignment Healthcare members to Sutter's comprehensive care network in Northern California [1][2] Group 1: Agreement Details - The renewed agreement applies to Alignment Healthcare members enrolled in Sutter Advantage HMO and My Choice PPO health plans, focusing on providing access to care for high-risk individuals with chronic conditions [2][4] - The collaboration aims to enhance patient experience and lower total care costs by leveraging the strengths of both organizations [3][4] Group 2: Expansion Plans - Sutter Health plans to open over 27 new ambulatory care sites, 27 urgent care centers, and 22 ambulatory surgery centers starting in 2025, addressing the ongoing national challenge of healthcare access [3] Group 3: Medicare Advantage Benefits - Medicare Advantage plans offer additional benefits beyond Original Medicare, including care coordination, disease management, in-home support, and limited annual out-of-pocket costs, which may lead to better health outcomes [5] Group 4: Company Profiles - Sutter Health is a not-for-profit healthcare system serving nearly 3.5 million patients with over 57,000 employees and 12,000+ affiliated physicians, focused on expanding care accessibility [6] - Alignment Health aims to empower seniors through high-quality, low-cost care, utilizing a customized care model and technology platform, AVA, to deliver coordinated care [8]

Financial Data and Key Metrics Changes - Health plan membership reached 189,100, growing approximately 59% year-over-year, exceeding initial guidance by over 25,000 members [5][21] - Total revenue for Q4 2024 was $701 million, a 51% year-over-year increase, and $2.7 billion for the full year, representing a 48% growth [6][21] - Adjusted gross profit for Q4 was $88 million, with a consolidated Medical Benefit Ratio (MBR) of 87.5%, improving by 200 basis points year-over-year [6][22] - Adjusted EBITDA was positive $1 million for Q4, marking the first year of adjusted EBITDA profitability as a public company [8][26] Business Line Data and Key Metrics Changes - The company reported a significant improvement in margin ratios across all key metrics, with adjusted gross profit for the full year at $303 million and an MBR of 88.8% [7][21] - Inpatient admissions per 1,000 for at-risk members improved to 149 in 2024, down from 156 in 2023 [22][23] Market Data and Key Metrics Changes - Membership in California grew by 28%, while ex-California markets saw over 100% growth, indicating strong performance outside California [11][12] - The company achieved a 5-star rating in Nevada and North Carolina, enhancing reimbursement from CMS and lowering costs [13] Company Strategy and Development Direction - The company focuses on Medicare Advantage as a care management business, emphasizing quality care over actuarial underwriting [9][10] - Future growth is expected to be driven by strong Stars ratings and the final phase-in of the V28 risk adjustment model, with a target of maintaining at least 4 stars for California members [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving membership growth of 20% or more in the coming years while balancing margin expansion objectives [18] - The company anticipates a favorable operating environment due to its differentiated care management approach and strong Stars performance [19][20] Other Important Information - The company ended 2024 with $471 million in cash and investments, significantly lowering its cost of capital [27] - For 2025, the company expects health plan membership to be between 227,000 and 233,000 members, with revenue guidance of $3.72 billion to $3.78 billion [28][30] Q&A Session Summary Question: Can you unpack the guidance for 2025 for adjusted EBITDA? - Management noted that the guidance reflects a prudent approach to the new aspects of the Part D program under the Inflation Reduction Act, with a conservative outlook on MLR [39][40] Question: What is the expected split of membership growth between California and non-California? - Management expects ex-California to grow materially faster than California, but California will still drive over 50% of total net member growth [45] Question: How do you see the MLR guidance for 2025 compared to peers? - Management highlighted that their MLR is expected to decrease slightly, contrasting with peers who may see larger increases due to various challenges [50][51] Question: What is the current raw star rating score for the California HMO contract? - Management confirmed that maintaining a 4-star rating is a priority, with potential to improve to 4.5 or 5 stars based on competitive positioning [63][66] Question: How is the cohort maturation tracking? - Management expressed confidence in the maturation of the 2024 cohort into 2025, with strong engagement metrics supporting this trend [72][75] Question: What are the expectations for cash flow and CapEx? - Management indicated expectations for approximately $30 million to $35 million in CapEx for 2025, with a strong cash position to support growth [80][82]

ORANGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the following conferences: Leerink Global Healthcare Conference on Tuesday, March 11, at 3:40 p.m. EDTKeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, at 10:30 a.m. EDT A webcast and replay of the presentations will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/. About Alignment HealthcareAlignment Health is championin ...

Core Insights - Alignment Healthcare (ALHC) reported a revenue of $701.24 million for Q4 2024, marking a year-over-year increase of 50.7% [1] - The company's EPS for the same period was -$0.16, an improvement from -$0.25 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $677.04 million by 3.58%, and the EPS also surpassed the consensus estimate of -$0.18 by 11.11% [1] Financial Performance Metrics - Medical Benefit Ratio was reported at 87.5%, better than the five-analyst average estimate of 89.4% [4] - Health Plan Membership at the end of the quarter was 189,100, exceeding the average estimate of 185,005 from four analysts [4] - Revenues from Other sources were $9.46 million, surpassing the estimated $7.48 million, reflecting a 48.3% increase compared to the previous year [4] - Earned Premiums revenue was $691.79 million, compared to the estimated $668.26 million, also showing a 50.7% increase year-over-year [4] Stock Performance - Over the past month, shares of Alignment Healthcare have declined by 14.1%, while the Zacks S&P 500 composite decreased by 2.2% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Company Performance - Alignment Healthcare reported a quarterly loss of $0.16 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.25 per share a year ago, representing an earnings surprise of 11.11% [1] - The company posted revenues of $701.24 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 3.58%, and showing significant growth from year-ago revenues of $465.39 million [2] - Over the last four quarters, Alignment Healthcare has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Outlook - The immediate price movement of Alignment Healthcare's stock will largely depend on management's commentary during the earnings call and future earnings expectations [3] - The stock has gained approximately 17% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $848.58 million, and for the current fiscal year, it is -$0.47 on revenues of $3.44 billion [7] - The estimate revisions trend for Alignment Healthcare is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical Services industry, to which Alignment Healthcare belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Performance - The company reported a net loss, highlighting challenges in achieving profitability amid increasing expenses[12]. - The net loss attributable to Alignment Healthcare, Inc. for 2024 was $128.0 million, compared to a net loss of $148.0 million in 2023, indicating a 13.5% improvement[458]. - The net loss for 2024 was $128,071, a reduction from a net loss of $148,173 in 2023, indicating an improvement in financial performance[473]. - The total stockholders' equity decreased to $100.9 million in 2024 from $158.1 million in 2023, a decline of 36.2%[456]. - The company recorded a net income tax expense of $21 for the year ended December 31, 2024, compared to a benefit of $(22) in 2023[564]. - The equity in loss of subsidiary was $125,892 in 2024, compared to $147,529 in 2023, showing a decrease in losses from subsidiaries[616]. Revenue and Expenses - Total revenues for the year ended December 31, 2024, were $2,703.6 million, representing a 48.3% increase from $1,823.6 million in 2023[458]. - Medical expenses for 2024 amounted to $2,406.9 million, up 48.2% from $1,622.6 million in 2023[458]. - Premium revenue for 2024 was $2,666,813, a substantial increase from $1,668,131 in 2023, demonstrating strong growth in the Medicare Advantage sector[476]. - Capitation revenue for 2024 was $5,118, a decrease from $132,802 in 2023, indicating a shift in revenue sources[476]. - The total incurred medical expenses for the current year reached $832,819 million in 2024, significantly higher than the $492,315 million incurred in 2023[551]. - Medical expenses payable rose to $289.8 million in 2024, up 40.9% from $205.4 million in 2023[456]. Assets and Liabilities - Total current assets increased to $661.6 million in 2024 from $483.5 million in 2023, reflecting a growth of 36.8%[456]. - The company's total assets reached $782.1 million as of December 31, 2024, compared to $591.9 million in 2023, marking a 32.2% increase[456]. - Long-term debt increased significantly to $321.4 million in 2024 from $161.8 million in 2023, representing a 98.7% rise[456]. - The total liabilities rose to $325,182 in 2024 from $1,319 in 2023, reflecting a substantial increase due to new debt issuance[612]. - Cash and cash equivalents at the end of 2024 were $432,859, compared to $204,904 at the end of 2023, reflecting a significant increase in liquidity[465]. Investments and Financial Instruments - As of December 31, 2024, the company held $71.1 million in U.S. Treasury bills classified as held to maturity[436]. - The carrying value of U.S. Treasury bills decreased from $117,337 million in 2023 to $71,120 million in 2024, reflecting a significant reduction in investments[538]. - The company had $469,373 million in excess of FDIC-insured limits as of December 31, 2024, compared to $316,977 million in 2023, indicating increased cash reserves[520]. - As of December 31, 2024, the company had restricted investments in U.S. Treasury bills amounting to $1,033 million and certificates of deposits totaling $2,321 million[542]. Operational Efficiency and Management - The company is focused on maintaining high ratings on the Five Star Quality Rating System to enhance its competitive position[12]. - The company entered into a management services and risk management agreement with a third-party healthcare company in 2024, which is expected to enhance operational efficiency[481]. - The company’s management team has limited experience managing a public company, which may impact future performance[12]. Regulatory and Compliance - Medicare Advantage Plans in California, North Carolina, Nevada, Arizona, Texas, and Florida are subject to a minimum annual medical loss ratio (MLR) of 85%[486]. - The company is required to remit a portion of premiums back to the federal government if the minimum MLR is not met, although amounts payable were immaterial as of December 31, 2024[486]. - The Inflation Reduction Act is expected to have an immaterial impact on the company's consolidated financial statements at December 31, 2024, with provisions set to take effect over the next seven years[511]. Shareholder and Equity Information - The weighted-average common shares outstanding increased to 190.8 million in 2024 from 186.2 million in 2023, an increase of 2.8%[458]. - As of December 31, 2024, there were 8,762,481 stock options outstanding with a weighted-average exercise price of $16.97[571]. - The company granted 6,994,001 restricted stock units (RSUs) in 2024, with unvested and outstanding RSUs totaling 13,344,685 at year-end[575]. - Total equity-based compensation expense was $71,132, an increase from $66,835 in 2023[580]. Legal and Contingent Liabilities - The company accrued a potential liability of $913 related to a class action lawsuit as of December 31, 2024[599].

Financial Performance - Total revenue for Q4 2024 was $701.2 million, up 50.7% year-over-year, while full-year revenue was $2,703.6 million, up 48.3% year-over-year[8] - Adjusted EBITDA for Q4 2024 was $1.4 million, with a net loss of $(31.1) million, compared to a net loss of $(47.2) million in Q4 2023[8] - Adjusted gross profit for Q4 2024 was $87.9 million, compared to $49.2 million in Q4 2023[8] - Total revenues for 2024 reached $2,703,561, a 48.3% increase from $1,823,630 in 2023[17] - Earned premiums increased to $2,671,931 in 2024, up 48.3% from $1,800,933 in 2023[17] - Total expenses for 2024 were $2,805,116, a 43.8% increase compared to $1,951,447 in 2023[17] - Net loss for 2024 was $128,071, an improvement from a net loss of $148,173 in 2023[19] - Net loss per share attributable to Alignment Healthcare, Inc. improved to $(0.67) in 2024 from $(0.79) in 2023[17] Membership Growth - Health plan membership reached 189,100 as of December 31, 2024, representing a 58.6% increase year-over-year[7] - The midpoint of 2025 health plan membership guidance was raised by 2,000 due to strong open enrollment momentum[7] Cash and Assets - Cash and cash equivalents increased to $432.9 million as of December 31, 2024, up from $202.9 million in 2023[16] - Cash and cash equivalents at the end of 2024 were $432,859, compared to $204,954 at the end of 2023[20] - Total assets grew to $782.1 million as of December 31, 2024, compared to $591.9 million in 2023[16] Debt and Financial Position - Long-term debt increased to $321.4 million as of December 31, 2024, up from $161.8 million in 2023[16] - Net cash provided by operating activities was $34,770 in 2024, a recovery from a cash used of $(59,187) in 2023[20] Future Guidance - The company introduced 2025 revenue guidance of $3.72 billion to $3.78 billion, indicating a year-over-year growth of 37.6% to 39.6%[7] Operational Metrics - Medical benefits ratio based on adjusted gross profit was 87.5% for Q4 2024, compared to 88.8% for the full year 2024[8] - Adjusted EBITDA is used by management to assess operating performance, although specific figures were not disclosed in the provided content[23] - Medical Benefits Ratio (MBR) is calculated by dividing total medical expenses by total revenues, although specific MBR figures were not provided[25] Strategic Initiatives - The company plans to continue evaluating acquisition opportunities as part of its business strategy[22]